BRD4-mediated repression of p53 is a target for combination therapy in AML
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRD4-mediated repression of p53 is a target for combination therapy in AML
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-11
DOI
10.1038/s41467-020-20378-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Investigational non-JAK inhibitors for chronic phase myelofibrosis
- (2020) Aniket Bankar et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- SynergyFinder 2.0: visual analytics of multi-drug combination synergies
- (2020) Aleksandr Ianevski et al. NUCLEIC ACIDS RESEARCH
- Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones
- (2018) Bauke de Boer et al. CANCER CELL
- Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models
- (2018) Waleed Minzel et al. CELL
- Targeting the MTF2-MDM2 axis sensitizes refractory acute myeloid leukemia to chemotherapy
- (2018) Harinad B. Maganti et al. Cancer Discovery
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Short Isoform of BRD4 Promotes HIV-1 Latency by Engaging Repressive SWI/SNF Chromatin-Remodeling Complexes
- (2017) Ryan J. Conrad et al. MOLECULAR CELL
- Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function
- (2017) Jun-ichi Sakamaki et al. MOLECULAR CELL
- Census and evaluation of p53 target genes
- (2017) M Fischer ONCOGENE
- p53−/−synergizes with enhancedNrasG12Dsignaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia
- (2016) Jingfang Zhang et al. BLOOD
- Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
- (2016) Brian K. Albrecht et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells
- (2016) Z Xu et al. LEUKEMIA
- 53BP1 Integrates DNA Repair and p53-Dependent Cell Fate Decisions via Distinct Mechanisms
- (2016) Raquel Cuella-Martin et al. MOLECULAR CELL
- Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
- (2016) Sheela A. Abraham et al. NATURE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- An update of current treatments for adult acute myeloid leukemia
- (2015) H. Dombret et al. BLOOD
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
- (2015) M. Andreeff et al. CLINICAL CANCER RESEARCH
- Phenotype Specific Analyses Reveal Distinct Regulatory Mechanism for Chronically Activated p53
- (2015) Kristina Kirschner et al. PLoS Genetics
- Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
- (2014) A Moros et al. LEUKEMIA
- Drugging the p53 pathway: understanding the route to clinical efficacy
- (2014) Kian Hoe Khoo et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
- (2013) Shwu-Yuan Wu et al. MOLECULAR CELL
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
- (2013) Helen Jayne Susan Stewart et al. Cancer Medicine
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal
- (2010) Z. Zhao et al. GENES & DEVELOPMENT
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- ChIP-seq: Using high-throughput sequencing to discover protein–DNA interactions
- (2009) Dominic Schmidt et al. METHODS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More